Abstract
Gastrin-releasing peptide (GRP) has been proposed as a major growth factor in brain tumors, and GRP receptor (GRPR) antagonists show antiproliferative effects in experimental gliomas. However, the underlying molecular events downstream of GRPR activation remain poorly understood. In the present study, we examined the role of the GRPR in regulating proliferation of glioma cells in vitro and its possible interaction with the phosphatidylinositol 3-kinase (PI3K) signaling pathway. Expression of GRPR mRNA and protein in C6, U-87MG, and U-373MG glioma cells was analyzed by reverse transcriptase polymerase chain reaction (RT-PCR) and immunohistochemistry. Proliferation of C6 and U-87MG, but not U-373MG cells was significantly inhibited by the GRPR antagonist RC-3095, whereas the GRPR agonist bombesin (BB) significantly enhanced proliferation of C6 cells. The BB-induced stimulatory effect on cell proliferation was prevented by either RC-3095 or the phosphatidylinositol 3-kinase (PI3K) inhibitor LY294002. Our results provide the first evidence that the GRPR regulates proliferation of C6 glioma cells and suggest that PI3K is required for GRPR-mediated stimulation of glioma growth.
Keywords: Bombesin-like peptides, gastrin-releasing peptide receptor, RC-3095, phosphoinositide 3-kinase, glioma, brain tumor
Current Neurovascular Research
Title: Gastrin-Releasing Peptide Receptors Regulate Proliferation of C6 Glioma Cells through a Phosphatidylinositol 3-Kinase-Dependent Mechanism
Volume: 5 Issue: 2
Author(s): Debora Gazzana Flores, Caroline Brunetto de Farias, Juliano Leites, Marianne Schrader de Oliveira, Rodrigo Cruz Lima, Alessandra Sayuri Kikuchi Tamajusuku, Luciane Pons Di Leone, Luise Meurer, Algemir Lunardi Brunetto, Gilberto Schwartsmann, Guido Lenz and Rafael Roesler
Affiliation:
Keywords: Bombesin-like peptides, gastrin-releasing peptide receptor, RC-3095, phosphoinositide 3-kinase, glioma, brain tumor
Abstract: Gastrin-releasing peptide (GRP) has been proposed as a major growth factor in brain tumors, and GRP receptor (GRPR) antagonists show antiproliferative effects in experimental gliomas. However, the underlying molecular events downstream of GRPR activation remain poorly understood. In the present study, we examined the role of the GRPR in regulating proliferation of glioma cells in vitro and its possible interaction with the phosphatidylinositol 3-kinase (PI3K) signaling pathway. Expression of GRPR mRNA and protein in C6, U-87MG, and U-373MG glioma cells was analyzed by reverse transcriptase polymerase chain reaction (RT-PCR) and immunohistochemistry. Proliferation of C6 and U-87MG, but not U-373MG cells was significantly inhibited by the GRPR antagonist RC-3095, whereas the GRPR agonist bombesin (BB) significantly enhanced proliferation of C6 cells. The BB-induced stimulatory effect on cell proliferation was prevented by either RC-3095 or the phosphatidylinositol 3-kinase (PI3K) inhibitor LY294002. Our results provide the first evidence that the GRPR regulates proliferation of C6 glioma cells and suggest that PI3K is required for GRPR-mediated stimulation of glioma growth.
Export Options
About this article
Cite this article as:
Flores Gazzana Debora, de Farias Brunetto Caroline, Leites Juliano, de Oliveira Schrader Marianne, Lima Cruz Rodrigo, Kikuchi Tamajusuku Sayuri Alessandra, Di Leone Pons Luciane, Meurer Luise, Brunetto Lunardi Algemir, Schwartsmann Gilberto, Lenz Guido and Roesler Rafael, Gastrin-Releasing Peptide Receptors Regulate Proliferation of C6 Glioma Cells through a Phosphatidylinositol 3-Kinase-Dependent Mechanism, Current Neurovascular Research 2008; 5 (2) . https://dx.doi.org/10.2174/156720208784310240
DOI https://dx.doi.org/10.2174/156720208784310240 |
Print ISSN 1567-2026 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5739 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
CXCR4 Receptor as a Promising Target for Oncolytic Drugs
Mini-Reviews in Medicinal Chemistry DNA Drug Design for Cancer Therapy
Current Pharmaceutical Design Preparation, Chemical and Electrical Characterizations of Lipid Nanoparticles Loaded with Dihydroxybenzophenone
Medicinal Chemistry EDITORIAL [Hot topic: New Therapeutic Advances and Perspectives in Tumour Angiogenesis (Guest Editor: Eddy Pasquier)]
Current Cancer Drug Targets Phytoconstituents of <i>Lantana camara</i> L.: Rekindling Hope in the Cancer Treatment
Current Bioactive Compounds Target Therapies in Pancreatic Carcinoma
Current Medicinal Chemistry Matching Chelators to Radiometals for Positron Emission Tomography Imaging- Guided Targeted Drug Delivery
Current Drug Targets Oxidative Stress and Mitochondrial Dysfunction in Type 2 Diabetes
Current Pharmaceutical Design Influence of Aldo-keto Reductase 1C3 in Prostate Cancer - A Mini Review
Current Cancer Drug Targets Molecular Link Mechanisms between Inflammation and Cancer
Current Pharmaceutical Design Restoring TRAIL Induced Apoptosis Using Naturopathy. Hercules Joins Hand with Nature to Triumph Over Lernaean Hydra
Current Genomics Gemini Surfactant Based Carriers in Gene and Drug Delivery
Current Medicinal Chemistry Gene Therapy Approaches for the Selective Killing of Cancer Cells
Current Pharmaceutical Design Intracellular Calcium, Endothelial Cells and Angiogenesis
Recent Patents on Anti-Cancer Drug Discovery Active Targeting Strategies for Anticancer Drug Nanocarriers
Current Drug Delivery CRISPR-Cas9, A Promising Therapeutic Tool for Cancer Therapy: A Review
Protein & Peptide Letters Regulation of Microtubule: Current Concepts and Relevance to Neurodegenerative Diseases
CNS & Neurological Disorders - Drug Targets G-Protein Signaling, Lipid Rafts and the Possible Sites of Action for the Antidepressant Effects of n-3 Polyunsaturated Fatty Acids
CNS & Neurological Disorders - Drug Targets Recent Patents in Circulating Cell-Free Tumor DNA as Biomarker in Cancer
Recent Patents on Biomarkers Targeted Therapies in Gynecologic Cancers
Current Cancer Drug Targets